Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: RevMikeB who wrote (23444)	7/22/1998 6:51:00 PM
From: Machaon	Read Replies (1) \| Respond to of 32384

<< There is a downside though: when drugs are approved, the news gets to everyone more so than at any other time for biotechs. >> Well...... there is one other time: Earnings report time. << Off-label use is harder to predict since Doctors might not know about using Targretin as other treatments or they might be less inclined to do it without FDA approval. >> Under new FDA guidelines, if I remember them correctly, drug companies only have to show efficacy in Clinical trials in order for doctors to be able to legally prescribe the drug for off-label. So it depends upon how well Ligand executes this side of their business. From their 1997 annual report: "In Parallel, the Company is conducting Phase II clinical trials in several types of cancer and dermatological disorders that have larger patient populations to determine future Phase III trials and to provide physicians with valuable information about additional activity of the drugs" Good luck, Bob